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Abstract
The influence of microbial factors on adverse perinatal outcomes has become the focal point of recent
investigations, with particular interest in the role of the microbiome and probiotic interventions. The purpose of
this scoping review was to identify and critique the most recent evidence about these factors as they relate to
pregnancies complicated by preeclampsia (PEC), preterm birth (PTB), and gestational diabetes mellitus (GDM).
Four databases (PubMed, EMBASE, Web of Science, and Cochrane) were searched for articles published in
English in the last 10 years with the concepts of the microbiome, probiotics, and PEC, PTB, or GDM. Forty-nine
articles were eligible for full-text review. Five articles were excluded, leaving 44 articles that met all the eligibility
criteria. The relationships between the microbiome and the risk for PEC, PTB, and GDM are not fully elucidated,
although probiotic interventions seem beneficial in decreasing PEC and GDM risk. Probiotic interventions
targeting bacterial vaginosis and elimination of infection in women at risk for PTB appear to be beneficial. More
research is needed to understand the contributions of the microbiome to adverse perinatal outcomes. Probiotic
interventions appear to be effective in reducing risk for select outcomes.
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Introduction
Pregnancy is characterized by a variety of microbiological, immunologic, and inflammatory changes that
promote the health of both the mother and the developing fetus.1,2 The microbiome composition of the
maternal gut changes dramatically between the first and third trimesters of pregnancy. These changes include
increased β-diversity (differences between pregnant women), an overall increase in proteobacteria and
actinobacteria, and reduced richness (lower number of species).3 Similarly, the vaginal microbiome composition
changes substantially during the course of normal pregnancy. Diversity decreases, stability increases, and the
vagina is enriched with Lactobacillus species.4 Vaginal pH becomes more acidic, while vaginal secretions are
increased. However, by the third trimester, the vaginal microbiota resembles that of the nonpregnant state.4
Host microbial interactions between the mother and the infant during pregnancy and the timing of the first
exposure of the fetus to maternal microbes are not fully understood, although the largest exposure is thought to
occur at birth.5 Historically, the intrauterine environment was thought to be germ-free; however, newer
evidence suggests that a bacterial milieu may be present in the fetoplacental circuit.4,6,7 Microbial exposures and
alterations have been implicated in the etiology of several adverse perinatal outcomes, including preeclampsia
(PEC), preterm birth (PTB), and gestational diabetes mellitus (GDM).8,9 Recent investigations exploring the
contributions of the human microbiome (defined as the total collection of microbes and their genetic
characteristics)10 have become the focus of recent scientific inquiry in understanding the etiologic mechanisms
of these obstetrical syndromes.11–13

Background
Completed in 2012, the Human Microbiome Project characterized microbial communities and their respective
physiologic activities in a variety of body sites, including the nasal passages, oral cavity, urogenital system, and
gastrointestinal tract.14 The initiative generated health reference data for a variety of microbiome sites,
including those associated with normal pregnancy.3,4 Utilizing advanced molecular genetics and genomics
technology, a variety of DNA-sequencing technologies including 16S (gene)-based analysis, as well as whole
genome shotgun sequencing (entire bacterial DNA sequence of an organism), have allowed for both
characterization of the types of microbes present in select body sites, as well as their genetic coding patterns
and metabolic capacity.15,16 Advances in genomic analyses and the development of bioinformatics
communication channels, such as Quantitative Insights into Microbial Ecology and Mothur (a microbiome
software platform), have streamlined the process of sharing the taxonomic information identified in these

analyses.17,18 Furthermore, these bioinformatic resources provide detailed information about the composition of
body sites and the influence on host physiology, which are key in understanding health outcomes.
The closely related area of microbial interventions has received considerable attention worldwide. Probiotic
interventions contain live, usually freeze-dried bacterial microbes, often from the Lactobacillus and/or
Bifidobacterium genera.19 When given in sufficient quantities, probiotic bacteria confer health benefits on the
host.20 Probiotics are considered food. For use in antenatal applications, probiotic interventions can be
administered either orally or vaginally. In most studies involving pregnant women, the oral route was used.19
Prebiotic interventions administered orally are not live bacteria but rather comprise indigestible food
substances, such as dietary fibers, certain starches, and oligosaccharides that are selectively fermentable.21
Prebiotics are food for the probiotic bacteria and therefore increase microbial numbers. Synbiotics are a
combination of probiotic and prebiotic interventions.22 Synbiotics produce beneficial effects by promoting the
survival of the live microbes in the gut by stimulating growth and/or metabolic activity of one or more probiotic
bacteria. Probiotic interventions and, to a lesser extent, prebiotics have been applied during pregnancy to
improve maternal and fetal outcomes.19 More recently, synbiotic antenatal interventions have been studied.23,24
The purpose of this scoping review is to explore and synthesize the scientific evidence about the maternal and
neonatal consequences of microbial dysbiosis, with a focus on the role of the microbiome during pregnancy, as
well as the influence of prebiotic and probiotic exposures. Specifically, this review outlines the most recent
literature on perinatal microbiome and probiotics, prebiotics, and synbiotics specific to the maternal and
neonatal outcomes in pregnancies that are complicated by PEC, PTB, or GDM. A brief review of the implications
for the neonate as well as future clinical and research implications is discussed.

Methods
A comprehensive literature search of 4 databases (PubMed, EMBASE.com, Web of Science Core Collection, and
the Cochrane Database of Systematic Reviews) was undertaken to identify relevant articles. A scoping review
strategy was chosen as the review method, as research studies investigating the impact of microbiome and
probiotics on adverse perinatal outcomes have not been comprehensively explored.25 To ensure that the full
breadth and depth of the literature were explored, the searches were developed and conducted by an
experienced medical librarian with input from the research team. This review was conducted using the
standards established by the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses)
guidelines, which advocate for systematic and reproducible methods. Search strategy details are provided in
Table 1. The results were exported to Endnote and reviewed by the clinical authors.
Table 1. PubMed.gov search strategiesa
Preeclampsia
((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR prebiotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR
"prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab])
AND (preeclampsia[tiab] OR pre-eclampsia[tiab] OR "Pre-Eclampsia"[Mesh])) AND
("2008/08/10"[PDAT] : "2018/08/10" [PDAT]) AND english[All Fields])
Preterm birth
((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR prebiotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR
"prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab])
AND ("Premature Birth"[Mesh Terms] OR “premature birth"[tiab] OR “preterm birth"[tiab]
OR “pre-term birth"[tiab])) AND ("2008/08/10"[PDAT] : "2018/08/10"[PDAT]) AND
english[All Fields])
Gestational
((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR prediabetes
biotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR
mellitus
"prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab])

AND ("Diabetes, Gestational"[Mesh] OR “gestational diabetes”[tiab])) AND
("2008/08/10"[PDAT] : "2018/08/10"[PDAT]) AND english[All Fields])
Data searched August 10, 2018, Chrome browser.
Articles were included if published in English between January 1, 2008, and August 10, 2018, to capture the
most recent evidence in line with the Human Microbiome Project that launched in 2008. The searches combined
controlled vocabulary supplemented with key words related to the concepts of the microbiome (eg, microbiota,
prebiotics, probiotics, synbiotics); PEC (eg, preeclampsia, eclampsia); GDM (eg, pregnancy, diabetes mellitus);
and PTB (eg, preterm birth, premature birth). Gray literature (eg, scholarly but not commercially published
documents such as conference abstracts or proceedings, government reports, white papers, and theses) was not
included.
Following the database searches, articles were selected if they met the inclusion criteria: (a) reported findings
about PEC, GDM, or PTB AND; (b) reported outcomes of prebiotic and probiotic interventions; or (c) evaluated
the composition of the maternal microbiome. Article quality was not assessed, but rather the types of studies
were categorized to offer the most comprehensive review of the state of the science on the topics. The articles
included in this scoping review were limited to level 1 experimental designs (randomized controlled trials [RCTs]
or systematic reviews of RCTs); level 2 quasi-experimental designs; level 3 observational analytic designs
(systematic review of cohort study, cohort study with control group, case-control study); and level 4
(observational descriptive and cross-sectional studies).26 Titles and abstracts were initially reviewed to
determine first round inclusion; full text was later reviewed for final decisions about inclusions. Articles were
excluded if not directly related to the select perinatal outcomes (PEC, GDM, PTB), or if the study did not clearly
measure the microbiome, prebiotic, probiotic, or symbiotic-related concepts. The PRISMA flow diagram is
presented in Figure 1. A series of tables are used to present the literature. Table 2 contains the systematic
reviews and meta-analyses.28–36Table 3 presents the findings of individual trials: RCTs, prospective cohort
studies, retrospective cohort studies, and a case-control study.23,24,37–50 Studies of the microbiome and the
perinatal outcomes of PEC, GDM, and PTB are presented in Table 4.12,51–67

Figure 1. PRISMA 2009 flow diagram. For more information, visit www.prisma-statement.org. From Moher et
al.27

Table 2. Systematic review and meta-analyses
Author (year)

Articles
included

Intervention if
applicable

x

7

Probiotics

↓ preeclampsia (OR = 0.80,
95% Cl: 0.66-0.96) and severe
preeclampsia (OR = 0.61,
95% Cl: 0.43-0.89)

x
x

1
7

Probiotics
Probiotics

↓ diagnosis of GDM (P = .03)

Lindsay et al28 (2013)

x

7

Probiotics

Pan et al31 (2017)

x

x

6

Probiotics

Taylor et al32 (2017)

x

x

4

Probiotic

x

10

Probiotics

x

49

Probiotic
Prebiotic

Preeclampsia (PEC)
Lindsay et al28 (2013)a

Gestational diabetes
mellitus (GDM)
Barrett et al29 (2014)
Dallanora et al30
(2018)

Systematic
review

Zheng et al33 (2018)

Spontaneous
premature labor (sPTL)
and/or premature
birth (sPTB)
Jarde et al34 (2018)

x

Metaanalysis

Findings related to
intervention if applicable
Significant

↓ fasting serum insulin (P =
.00001), HOMA (P = .02)
↓ HOMA (P = .01)

↓ fasting serum insulin (P =
.0001), HOMA (P = .03)

Nonsignificant of (NA) statistics
not provided
NA: ↓preeclampsia

NA: Probiotics may improve
glycemic control, ↓ VLD
Cholesterol, ↓ inflammatory
marker
NA: ↓ fasting blood glucose,
incidence of GDM
FBS (P = .9), gestational age (P =
.63), birth weight (P = .9)
FBS (P = .96), LDL-cholesterol (P =
.67), weight gain, mode of birth,
neonatal outcomes, adverse events
(P levels not reported)
FBS (P = .26), lipid levels (P = .71),
HDL cholesterol (P = .87), LDL
cholesterol (P = .97), triglycerides
(0.29)

PTL <34 wk (P = .96), or <37 wk (P =
.96); PTL <37 wk (P = .73), or <37
wk (P = .83)

Mendz et al35 (2013)

x

13

N/A

↓ genital infection with
probiotics (P = .00096)

NA: Vaginal bacteria were the most
common source of intra-amniotic
infection
36
Othman et al (2007)
X
x
3
Probiotics
PTB <32 wk (P = .79), PTB <37 wk (P
= .26)
Abbreviations: CI, confidence interval; FBS, fasting blood sugar; HDL, high-density lipoprotein; HOMA, homeostatic model assessment for insulin
resistance; LDL, low-density lipoprotein; OR, odds ratio; VLD, very low density.
a
Same systematic review noted later.
Table 3. Summary of probiotics studies
Author (year)

Study design

Total
participants

Dolatkhah et al40
(2015)

RCT

64-GDM

Hajifaraji et al41
(2018)
Jafarnejad et al42
(2016)

RCT

GDM

RCT

82-GDM

Karamaliet al43
(2016)

RCT

60-GDM

Sample and
microbial
intervention a
32-Probiotic
32-Placebo

Purpose

Probiotic
Inflammation
41-Probiotic
41-Placebo

Oxidative stress

30-Probiotic
30-Placebo

Glucose
metabolism
Weight gain

Glycemic
control
Inflammatory
status
Glycemic
control
Lipid profiles

Findings related to
intervention
Significant

Nonsignificant

↓pregnancy weight
gain study weeks 5
and 6(P < .05), FBS (P
< .05), insulin
resistance index (P <
.05)

Pregnancy weight gain (study
weeks 1-4)

↓IL-6 (P = .04), TNF-α

FBS, HbA1c, HOMA, IL-10, insulin
levels

(P = .04), hs-CRP (P =
.03)
↓FBS (P < .001),
serum insulin levels (P
< .001), HOMA (P =
.03), insulin sensitivity
(P < .0007),
triglycerides (P = .03),
VLD cholesterol (P =
.03)

Lipid profiles

Kijmanawat et al44
(2018)

RCT

60-GDM

28-Probiotic
29- Placebo

Insulin
Resistance

↓FBS (P = .34),
fasting plasma insulin
(P = .001), HOMA (P

Pregnancy weight gain

= .001)
Lindsay et al
(2015)

45

RCT

149-GDM

74-Probiotic
75 Placebo

Metabolic
health

↓Total cholesterol (P

FBS (P = .588), insulin (P =

= .031), LDL

.927), HOMA (P = .875), C-

cholesterol (P = .011)

peptide (P = .843), HDL
cholesterol (P = .341),
triglycerides (P = .687), HDL

Luoto et al46
(2010)

RCT

256 gravidas

Nabhani et al23
(2018)

RCT

90-GDM

Wickens et al47
(2017)

RCT

Healthy
pregnant
women

67-Probiotic
and dietary
intervention
63-Placebo
and dietary
intervention
85-Control and
placebo
48-Synbiotic
49-Placebo

212-Probiotic
211-Placebo

Pregnancy
outcome and
prenatal and
postnatal
growth

Insulin
resistance
Lipid profile
Total
antioxidant
capacity

Probiotic plus dietary
intervention ↓GDM
(P = .003)

The symbiotic
intervention resulted
in decreased LDLs
from baseline (P <
.05). ↓ SBP and DBP
in symbiotic group
compared with
placebo (P < .05).
GDM prevalence ↓GDM in women
aged ≥35 y(P = .009)
and women with
history of GDM (P =
.004)

ratio (P = .704), LDL ratio (P =
.244)

FBS, insulin
resistance/sensitivity, lipid
profile, TAC indices symbiotic
group compared with placebo (P
< .05).

Overall GDM prevalence (P =
.08)

Spontaneous
premature labor
(sPTL) and/or
spontaneous
premature birth
(sPTB)
Kirihara et al48
(2018)

Retrospective
cohort

121

45-Probiotic
76-Controls

Perinatal
outcomes sPTB

↑Gestation age (P =
Funisitis (P = .052), birth weight
(P = .021)
.012), ↓sPTB <32 wk
(P = .001), ↓CAM (P =
.03), ↓vaginal
Lactobacillus (P = .052)
Preliminary results: sPTD <34 wk
(P = .31), sPTD <37 wk (P = .14)

Krauss-Silva et al49
(2011)

RCT

644
asymptomatic
gravidas

320-Probiotic
324-Placebo

Prevention of
PTB-associated
BV

Myhre et al50
(2011)

Prospective
cohort study

23 822 healthy
gravidas

sPTB risk

↓sPTB with high
intake or probiotic
milk (P < .035)

Nordqvist et al39
(2018)

Prospective
cohort

37 050
Norwegian
women

950-Probiotic
milk
17 938controls
Probiotic milk

Intervention
timing and
incidence of PTL

Probiotic milk intake
during early
pregnancy intake
↓PTL (P = .03)

Dose response

Table 4. Summary Table of microbiome studies, often metagenomic-based
Author, year
Study design
Total
Microbiome
Findings
participation
site studied
Preeclampsia
DiGiulio et al51 Retrospective
62
Intra-amniotic Women with PEC with MIAC
(2010)
cohort
demonstrated a ↑ mean amniotic
fluid IL-6 level (P = .002).
Jaramillo et
Secondary
57
Oral
RCT was on subgingival scaling and
al52 (2012)
analysis of RCT
planning vs supragingival
prophylaxis
No differences in periodontopathic
organisms between the 2 groups.
Amarasekara
Nested case110:
Placenta
12.7% of the placenta samples of
et al12 (2015)
control
55 cases,
women with PEC were PCR positive
55 controls
for the 16S rRNA gene. Pathogenic
microbiome identified: Listeria,
Salmonella, and Escherichia.
Nizyaeva et
Case-control
32:
Placenta
25% of the PEC group demonstrated
53
al (2017)
20 cases,
pathologic microbial growth
12 controls
Control group placentas were
culture negative.
Placental microbes were identified
only in women with PEC who
delivered after 34 wk of gestation
Liu et al54
Case-control
100:
Gut
Women with PEC: there was an
(2017)
26 first trimester
overall ↑ in pathogenic bacteria.
24 second
Clostridium perfringens (P = .03) and
trimester
Bulleidia moorei
(P = .00) ↑ in women with PEC
24 third
decrease noted in the probiotic
trimester
bacteria Coprococcus catus (P = .03).
26 controls
Gestational
diabetes
Crusell et al55
(2018)

Prospective
cohort

50 GDM, 157
controls

Gut

Kuang et al56
(2017)

Exploratory
descriptive

124: 43 GDM, 81
healthy

Stool in
second
trimester

Wang et al57
(2018)

Descriptive

346 women with
GDM and 140 of
their NBs to total
of 581 women,
248 NBs = 1062
samples

Oral, pharynx,
GI, vagina,
meconium,
amniotic fluid

GDM associated with significant gut
microflora disruption similar to that
found in nonpregnant adults with
type 2 diabetes
Significant differences in
microbiomes of women with or
without GDM. ↓ diversity noted
with GDM women.
Lactobacillus iners strains were
significantly greater in those with
GDM (P< .05).
Also ↑ viral load in meconium of
NBs whose mothers have GDM.
Microbial variations showed
convergence across body sites with

Zheng et al58
(2013)

Descriptive
comparison

105, in 4 groups:
HP = 31, GDM =
39, T1DM =
35, HN = 32

Vagina, for
fungal flora

Preterm birth
Ardissone et
al59 (2014)

Descriptive

52 infants: (23-41
wk at birth)

Meconium

From RCT
(about allergy
prevention)
Prospective
cohort

335:
256 at 36 wk,
105 in labor
250 women with
history of early
loss

Vagina

Dahl et al62
(2017)

Prospective
cohort, case
control

121 births: 102
term, 19 = PTB

Stool at 4 d
postpartum

Doyle et al63
(2014)
.

Cross-sectional
study

989 258 (26.1%)
with chorio, 120
(12.1%) had
severe

Placenta

Avershina et
al60 (2017)
Brown et al61
(2018)

Vagina

more similar community structure in
those with GDM.
Fasting plasma glucose (FPG), 1- and
2-h plasma glucose levels, & HbA1c
were always ↑ in GDM and type 1
DM groups (P < .01).
Diversity in fungi greater by
pregnancy group, ↑ from 13, 17,
and 20 species respectively, in HP,
GDM, and TIDM groups
Gestational age prior to 33 wk at
birth had largest influence on
microbial community structure (P =
.029); mode of delivery (C/Sec vs
vaginal) also had effect (P = .044).
Associated bacteria seen in PTBs:
Enterobacter, Enterococcus,
Lactobacillus, Photorhabdus, and
Tannerella
Swabs at 36 wk or labor admission:
at labor onset had ↑ α-diversity and
↑ closer to labor.
In those with PTBs (38/250 = 15%)
compared with term births,
Lactobacillus was depleted prior to
PPROM (P = .026), which occurred
at mean gestational age of 30 wk,
and depletion persisted after
PPROM (P = .005). Dysbiosis also
occurred in women with high
amounts of Lactobacillus when
treated with erythromycin (P =
.00009), as did NB sepsis.
If PTBs, had lower α-diversity in gut
and significantly fewer OTUs in
genera of Bifidobacterium and
Streptococcus and families in
Clostridiales order (stats not
available).
Nonsevere chorioamnionitis
(defined as ≥25 neutrophils
granulocytes on average per 10 high
power field) showed difference in
community members, ↑ bacterial
load, higher phylogenetic diversity,
↓ species richness, and smaller
(shorter) newborns

Hyman et al64
(2014)

Prospective
cohort

88:
17 PTBs,
71 term births

Vagina

Subramaniam
et al65 (2016)

Retrospective,
stratified by
race, BV, and
PTB

40 prior taken
vaginal swabs at
21–25 wk, and
Nugent smears

Vagina

Tabatabaei
et al66 (2018)

Nested casecontrol in
cohort

Vagina

Wylie et al67
(2018)

Nested casecontrol in
prospective
cohort study

450:
17 early
SPTBs,
77 late SPTBs,
and 356
controls
60:
128 swabs
through PG

Vagina for
virome

Significant correlation between
race/ethnicity and diversity (used
Shannon Diversity Index).
Location of sampling matters (prefer
posterior fornix). Small sample size
with limited statistical analysis.
BV samples had greater diversity (P
< .05), with more abundant BVassociated bacteria.
Underpowered to compare PTB with
microbiome but may be that
changes in communities are linked
to sPTBs rather than specific
organisms.
↑ diversity (P < .05) in CST IV.
Presence of BV-associated
bacteria (Gardnerella vaginalis,
Atopobium vaginae, and
Veillonellaceae bacterium) also
associated with PTB
24 had PTBs (38.7%). African
American women were 65% of
sample.
Higher viral richness was
associated w/ PTB in total
sample (P = .0005) and African

American subgroup (P =
.0003). Both high diversity of
bacteria and viruses in first
trimester were associated with
↑ risk for sPTB (P = .01); l ↓
combined diversity with term
birth (P < .0001).
Abbreviations: CST IV, community state type 4; GDM, gestational diabetes mellitus; HN, healthy nonpregnant;
HP, healthy pregnant; IL, interleukin; MIAC, microbial invasion of the amniotic cavity; NB, newborn; OTUs,
operational taxonomic units are clustered, grouped sequences; PCR, polymerase chain reaction; PEC,
preeclampsia; PG, pregnancy; PPROM, preterm premature rupture of membraines; PTB, preterm birth; PTL,
preterm labor; RCT, randomized controlled trial; sPTB, spontaneous preterm birth; T1DM, type 1 diabetes
mellitus.
A total of 1264 articles were identified through the database searches. Duplicates (396) were excluded leaving
868 articles to be screened in the initial abstract-screening phase. Forty-nine were eligible for full-text review.
Five articles were excluded during the full-text review phase, leaving 44 articles that met all the eligibility criteria
for inclusion in this study. In the following sections, the most recent evidence related to PEC, GDM, and PTB will
be presented. Details of the types and dosages of prebiotic, probiotic, and synbiotic interventions are beyond
the scope of this review but can be found in the individual studies.

Results
The role of the microbiome in PEC
Preeclampsia is a multisystem pregnancy complication characterized by new-onset hypertension with
proteinuria, or evidence of systemic disease primarily in the liver and kidneys, with onset after 20 weeks of
gestation.68 The etiologic pathways of PEC are multifactorial and include maternal and fetal factors; however,
the full pathway is not fully elucidated. The disorder is characterized by impaired vascular function and
activation of maternal systemic inflammation in several organs, which can be aggravated by many factors,
including infection. Studies have shown that women with asymptomatic bacteriuria, urinary tract infection,
periodontal disease, and chronic pyelonephritis are at increased risk for PEC.51,69 As such, the current focus of
scientific inquiry has shifted to learning more about the role of the microbiome in the multifactorial pathway of
PEC.
One of the focal areas in recent microbiome studies of PEC is vascular dysfunction in the placenta, which has
been implicated as one of the leading pathways underpinning the disorder.68 In a nested case-control study,
researchers compared the placental tissue of women with PEC with normotensive women to screen the samples
for the presence of bacteria. Using polymerase chain reaction and next-generation sequencing methods, the
researchers found that 12.7% of the placenta samples of women with PEC were polymerase chain reaction
positive for the 16S rRNA gene. The microbiome of the samples identified a variety of commensal and
pathogenic bacteria, including Listeria, Salmonella, and Escherichia.12 Similarly, Nizyaeva et al53 explored the
differences in the histological and microbial features of PEC in a nested case-control study. The sample included
20 reproductive age women with the disorder and 12 normal controls, all of whom were between 26 and 39
weeks of gestation.53 Forty-five percent of the women with PEC demonstrated chronic villitis (P < .05) as
compared with the control group at 8%. All placentas were cultured; 25% of the PEC group demonstrated
pathologic microbial growth (including Streptococcus agalactiae or group B Streptococcus and Staphylococcus
warneri), while all the control group placentas were culture negative. Placental microbes were identified only in
women with PEC who delivered after 34 weeks of gestation, suggesting that microbial pathways may be
particularly important to consider in women during later pregnancy. Together, these study findings suggest that
microorganisms may contribute to an inflammatory response and support the role of microbial interactions in
the etiologic pathway of PEC.
Infection and inflammation have also been implicated in the complex pathway of PEC,69,70 with some focus on
the influence of microbes within the intrauterine cavity. In a retrospective cohort investigation, DiGiulio et al51
found that women with PEC who had microbial invasion of the amniotic cavity demonstrated a higher mean
amniotic fluid IL-6 level (P = .002). The prevalence of microbial invasion overall in women with PEC was found to
be low, although 3 of the 6 women with microbial invasion were positive for Sneathia/Leptotrichia spp,51 which
are microbiota associated with bacterial vaginosis (BV) and isolated cases of maternal bacteremia and fetal
demise.71,72 Although microbial invasion of the intra-amniotic environment has been identified in women with
PEC, more studies are needed to elucidate the pathways by which microbes influence the intrauterine
physiology.
The association between maternal periodontal disease and PEC risk was explored in 2 studies, a meta-analysis70
and a secondary analysis of an RCT.52 In a recent meta-analysis of 11 observational studies including 1118
women with PEC compared with 2798 women, researchers found that women with periodontal disease before
32 weeks of gestation had a 3.6-fold increased risk of PEC (odd ratio [OR] = 3.69; 95% confidence interval [CI] =
2.58-5.27) compared with women without gum disease.70 The risk was also increased if periodontal disease was
present 48 hours prior to delivery (OR = 2.68, 95% CI = 1.39-5.18), as well as within 5 days after delivery (OR =
2.22; 95% CI = 1.16-4.27). In a secondary analysis of an RCT conducted by Jaramillo et al,52 the subgingival
microbiota of 57 women with mild PEC were evaluated for differences related to a periodontal intervention
(subgingival scaling and planing vs supragingival prophylaxis). There were no differences found in reduction of

periodontopathic organisms between the 2 groups.52 Despite these findings, the relationship between the oral
microbiome and PEC risk remains hypothetical, as most of the current literature consists of proposed pathways
related to hematogenous spread of microbial pathogens from the oral environment.1,73–76 A variety of oral
microbial pathogens have been implicated in the etiology of PEC in previous studies, but not enough evidence
has been identified to support a causal link.77 More research is needed to determine whether there is an
association between the oral microbiome and PEC risk.
Preeclampsia has features similar to metabolic syndrome, as women with this condition often develop altered
glucose and lipid metabolism, insulin resistance, and endothelial damage.78 Given the role of the gut microbiota
in metabolism, a recent study by Liu et al54 evaluated the gut microbiome of women with PEC to determine
whether intestinal dysbiosis could be detected as a marker. One hundred women were grouped into 4
categories: 26 women with PEC and 3 healthy control groups in the first, second, and third trimesters of
pregnancy. The dominant bacterium present in all samples was Bacteroidetes; however, in PEC women there
was an overall increase in pathogenic bacteria. Specifically, Clostridium perfringens (P = .03) and Bulleidia moorei
(P = .00) increased in women with PEC, with a decrease noted in the probiotic bacteria Coprococcus catus (P =
.03). These findings suggest that there may be a shift in the gut microbial composition in women with PEC.
Overall, 5 groups of investigators studied the microbiome of PEC.12,51–54 In 2 studies, the placenta site was
analyzed12,53; in the remaining 3, the mouth,52 gut,54 or an intra-amniotic51 site was examined. Some findings
supported the association between pathogenic bacteria and PEC, but this was not a consistent finding.
Furthermore, specific pathogenic organisms were not identified in common between the studies on PEC.

Probiotic use and PEC
The pathophysiologic pathways underpinning PEC are complex and not fully elucidated; however, maternal
immune system dysregulation and infections were associated with PEC risk and severity.79 Probiotics are
thought to reduce both systemic and placental inflammation, thus reducing PEC risk.37 Probiotics such as
Lactobacillus acidophilus and L rhamnosus were shown to influence gene regulatory pathways and expression in
immune response pathways of the human gut mucosal lining,80 further supporting the exploration of probiotics
as an intervention to delay and reduce the incidence of PEC.
Several studies investigating the association between probiotic products and PEC suggest a beneficial effect of
probiotics in reducing PEC risk.28,37,39 A large prospective Norwegian Mother and Child Cohort Study was
conducted from 1999 to 2009 and included data from 108 000 pregnancies. Using these data, Brantsaeter et al37
conducted a prospective cohort study of the relationship between probiotic ingestion in early pregnancy and the
risk of PEC in a sample of 33 399 primigravidas.37 In Norway, there are 2 main probiotic milk products that are
consumed. The probiotic beverages deliver 108 probiotic bacteria per milliliter. Therefore, the authors calculated
the probiotic dose based on dietary recall of these standard products. The researchers categorized dietary
probiotic ingestion as follows: none, low, moderate, and high. Just more than 5% (1755 women) developed PEC.
High-level probiotic intake (median = 200 mL/d with daily ingestion or greater) was associated with a significant
reduction in all PEC (OR = 0.80, 95% CI: 0.66-0.96) and severe PEC (OR = 0.61, 95% CI: 0.43-0.89). These findings
were also reported in a systematic review by Lindsay et al,28 who explored the use of probiotics during
pregnancy with maternal outcomes, including PEC. Seven articles were identified in the review, although only 1
study was identified related to PEC risk. Nordqvist et al39 conducted a secondary analysis of the Norwegian
Mother and Child Cohort Study to explore probiotic intervention timing. Specifically, they analyzed probiotic
milk intake before pregnancy, during early pregnancy, and during late pregnancy, with PEC risk in nulliparous
women (n = 37 050). The researchers found that probiotic milk intake in late pregnancy, but not before or during
early pregnancy, was associated with lower PEC risk (OR = 0.80, 95% CI: 0.68-0.94).39 Together, these studies
suggest that probiotic intake was associated with reduced PEC risk.

While the etiology of PEC remains unclear, the markers of hypoxia, oxidative stress, and hemolytic pathways,
including hemolysis, elevated liver enzymes, and low platelets, have been observed in women with PEC.81
Therefore, the physiologic consequences of PEC extend beyond the maternal environment and contribute to
fetal complications. A study by Ekambaram et al38 investigated the antihemolytic and antioxidant efficiency of 2
probiotic yeasts (Monascus purpureus and Saccharomyces cerevisiae) on fetal cord blood red blood cells of
infants born to PEC mothers as compared with healthy normotensive controls. The red blood cells of the PEC
sample were found to have low antioxidant status (P < .05), increased oxidative stress, (P < .05), increased
nitrative stress (P < .05), and increased hemolysis (P < .001). Oxidative stress hemolysis decreased in the cord
blood red blood cells for both groups after incubation with both probiotic yeasts. Specifically, M purpureus
resulted in significant reactive oxygen radical scavenging (removal) (P < .001), and S cerevisiae resulted in
significant nitric oxide radical scavenging (removal) (P < .001). These findings hold promise that probiotics could
modulate oxidative stress in offspring.

The role of the microbiome in gestational diabetes mellitus
The normal physiologic adaptations of pregnancy provide for the metabolic needs of the growing fetus.
Gestational diabetes mellitus is defined as a carbohydrate intolerance with hyperglycemia with onset during
pregnancy that varies in severity.82 Gestational diabetes mellitus is a heterogeneous group of metabolic
disorders that impacts up to 14% of pregnancies.83 Between 20% and 50% of women with GDM will go on to be
diagnosed with type 2 diabetes within 5 years.84 Evidence has emerged that highlights the link between the gut
microbiome and metabolism. This has led researchers to hypothesize that the gut microbiome may impact
gestational metabolism and development of GDM.56 The microorganisms that colonize the gut influence the
metabolism of nutrients, hunger, satiety, and both lipid and glucose metabolism. Gestational diabetes mellitus
has been associated with subclinical inflammation that may lead to oxidative stress.41 Therefore, efforts to
prevent and treat GDM have included probiotic and/or dietary interventions. Outcomes studied include a
variety of metabolic and inflammatory markers.
Four groups of researchers examined the microbiome related to GDM.55–58 The sites cultured varied widely
between studies; stool was cultured in 2 studies,55,56 vaginal swabs to examine fungi were used in 1 study,58 and
in another study, both viruses and bacteria were examined from 3 sites in women (oral, gastrointestinal, and
vagina) and 4 sites from their newborns (oral, pharynx, meconium, and amniotic fluid).57 Dysbiosis was identified
more frequently in women with GDM, who also exhibited less overall microbial diversity.56 More pathogens
were found in women with GDM, including more viruses and fungal species.57 The relationships between
dysbiosis and GDM need to be more fully elucidated.

Probiotic use and gestational diabetes mellitus
Gestational diabetes mellitus probiotic and synbiotic interventions have been addressed in 9 RCTs and 7
systematic reviews and/or meta-analyses. In 7 of the RCTs, participants were randomized after GDM diagnosis
to probiotic or placebo groups.23,24,40,42–45 The effect of a probiotic intervention on inflammatory markers and
oxidative stress in GDM was the goal of 1 study.41 Other outcomes attributable to the probiotic intervention are
somewhat variable between RCTs. Both C-reactive protein and tumor necrosis factor were significantly
decreased among probiotic group participants compared with placebo in 2 studies.41,42 Women in the probiotic
intervention groups had lower rates of GDM than those taking placebos in 2 studies.46,47 Fasting blood glucose
was significantly decreased in probiotic group participants in 3 RCTs.40,43,44 A review of the metaanalyses/systematic reviews allowed more patterns to emerge. Two systematic reviews/meta-analyses have
near-identical findings.31,33 Probiotic interventions resulted in a significant decrease in fasting serum insulin and
HOMA model assessment for insulin resistance.29,31,33 Overall in the meta-analyses, outcomes related to lipids,
gestational age, and inflammatory markers did not reach statistical significance.

The role of microbiome in preterm birth
During pregnancy, the vagina is dominated by Lactobacillus species and characterized by less richness and
diversity, but more stability, than the nonpregnant vaginal microbiome.85 The bacteria of the vaginal
microbiome have been classified into 5 community state types (CSTs).60,86 CST-I to CST-III and CST-V are
characterized by high levels of specific species of Lactobacillus. Vaginal Lactobacilli species include L acidophilus,
fermentum, crispatus, and jensenii.87 These Lactobacilli contribute to a protective biofilm on the vaginal
mucosa.88 Some Lactobacillus species produce lactic acid that acidifies the vaginal mucosal surface and prevents
the adherence of pathogens.89 Probiotic bacteria also secrete other substances that are associated with vaginal
health (bacteriocins, vitamins, and cytokines).89
At least 30% of premature labors are associated with maternal infection.36,85,90,91 Microbial pathogens can reach
the uterine cavity through 3 routes that can lead to infection: (a) ascending from the vagina and cervix, (b)
retrograde seeding from the abdominal cavity through the fallopian tubes, and (c) hematogenous seeding
through the placenta.90 At the level of the maternal mucosal surface, some microorganisms secrete
phospholipase A2 that acts on phospholipids to form arachidonic acid, which ultimately converts to
prostaglandins (PG, PGE2, PGF2A). Other microorganisms secrete endotoxins that stimulate a cascade of
proinflammatory cytokines.91 These microbial pathways work together to magnify the inflammatory response
and contribute to the degradation of the collagen matrices of the cervix, fetal membranes, placenta, and
uterus.91
Among the studies reviewed, a number of studies were designed to examine the microbial aspects of these
inflammatory pathways to predict PTB. Preterm birth is associated with higher α-diversity (intraindividual) of
vaginal flora.64 The CST-IV60,86 is associated with BV and is characterized by mixed community types, enriched in
various anaerobic bacteria, with low levels of Lactobacillus. Bacterial vaginosis is a microbial dysbiosis associated
with a 40% increase in the risk of PTB.36 When BV occurs, there is a shift from a predominance of Lactobacilli
populations to a higher proportion of other organisms: Gardnerella vaginalis, Prevotella bivia, Mobiluncus sp,
Mycoplasma hominis, and Atopobium vaginae.86 This results in the characteristic vaginal secretions with a
number of common clinical findings, including pH 5.5 or greater, presence of clue cells, and positive whiff test.92
Therefore, probiotic interventions have been used to address the BV dysbiosis in an effort to reduce the risk of
PTB.
Nine groups of researchers examined the microbiome related to PTB.59–67 Three of the studies that examined
PTB do not lend themselves to comparison because each investigative group sampled a different body site.59,62,63
In the 6 studies60,61,64–67 that used vaginal microbial samples, all focused on BV-related assessments, including
CST-IV categorization, the presence of BV-associated bacteria, and/or a decrease in Lactobacillus dominance.
One study reported viruses present.67 In the systematic review by Mendz et al,35 the bacterial etiology of intraamniotic infections was examined. Vaginal organisms were responsible for most intra-amniotic infections.35
In 3 investigations, race was explored as a possible factor in PTB, in relationship to the microbiome.64,65,67 Hyman
et al64 reported that significant correlations were identified between race/ethnicity and diversity in the vaginal
microbiome. Using the Shannon Diversity Index as the measure, African American women had the greatest
diversity of microbes and Caucasians had the least (P = .003). Hispanics had the second most diverse vaginal
microbiome (P = .0082) compared with Caucasians. Caucasian women who experienced PTB had greater
microbial diversity than those who had term births (P = .00016).64 Wylie et al67 reported higher richness and
diversity in the virome of women who experienced PTBs in the total sample (P = .0005) and those in the African
American subgroup who had PTBs (P = .0003). For the entire sample, both high diversity of bacteria and viruses
in the first trimester were associated with the highest risk for spontaneous PTB (P = .01), while lower combined
diversity was associated with term birth (P < .0001). Subramaniam et al65 examined their small sample that was
stratified by race and determined that the microbiota did not differ by racial groups.

Probiotic use and preterm birth
Because of the variation in premature labor diagnosis in most studies reviewed, PTBs (<37 weeks and/or <34
weeks) were used as the primary study outcomes. Two systematic reviews and 4 clinical studies explored the
efficacy of probiotic interventions to reduce PTB risk. Othman et al36 conducted a systematic review of probiotic
interventions to prevent premature labor. Three studies met their inclusion criteria; the impact of probiotic
interventions on vaginal infection was based on 2 trials including a total of 99 participants. The researchers
found that probiotic use reduced the risk of genital infection by 81% (relative risk [RR]: 0.19; 95% CI: 0.08-0.48).
However, they found insufficient evidence for utility of probiotic intervention for the prevention of premature
labor.
Using participants in the Norwegian Mother and Child Cohort Study prospective cohort study, Myhre et al50
explored the relationship between the ingestion of probiotic containing yogurt products and premature labor,
using a sample of 18 888 Norwegian women. Probiotic intake was calculated using dietary histories and
operationally defined as low, average, or high. The average probiotic intake in the high group was 138.4 mL/d.
Between 2002 and 2007, there were 950 cases of PTB of less than 37 weeks. Women with the “highest” intake
of probiotic yogurt experienced significantly lower risk of PTB (P = .035; OR: 0.820; 95% CI: 0.681-0.986).
Jarde et al34 conducted a systematic review of pregnancy outcomes in women taking probiotics or prebiotics. In
2 meta-analyses, the authors found no evidence that probiotic interventions altered the incidence of PTB of less
than 34 weeks (RR: 1.03, 95%, CI: 0.29-3.64, I2: 0%, 1017 women in 5 studies) or PTB of less than 37 weeks (RR:
1.08, 95% CI: 0.71-1.63, I2: 0%, 2484 women in 11 studies). A significant limitation of these meta-analyses is the
inclusion of studies of women from high-risk groups, such as obese women28 and those with GDM.28,42 The
heterogeneity of the studies included in these meta-analyses makes interpretation of the findings difficult. For
example, only 1 of the 11 studies in the meta-analyses aimed to reduce PTB using a probiotic intervention.49
Krauss-Silva et al49 enrolled healthy pregnant women in an RCT using 2 Lactobacillus species (L rhamnosus GR-1
and L reuteri RC-14) aimed at treating asymptomatic BV infections and ultimately PTB of less than 34 weeks of
gestation. At the time of publication of preliminary findings, the study sample was insufficient to draw
conclusions about intervention efficacy. More recently, Kirihara et al48 studied women at high risk for PTB in an
RCT. Bacterial vaginosis was prophylactically treated with a probiotic combination product (S faecalis,
Colstridium butyricum, and Bacillus mesentericus) versus a placebo from 12.5 ± 5 weeks until the time of birth.
Findings demonstrated that women in the probiotics group had significantly less spontaneous PTB, increased
gestational age, decreased intrauterine infections, and higher rates of normal vaginal flora.

Discussion
There was significant variation in the findings from studies investigating role of the microbiome during
pregnancy, as well as the influence of prebiotic, probiotic, and synbiotic exposures in women with PEC, GDM,
and PTB. Some findings supported the association between pathogenic bacteria and these perinatal outcomes,
but this was not a consistent finding. Furthermore, specific pathogenic organisms were not identified in
common between studies. Probiotic exposures appear to have a beneficial effect in decreasing PEC and GDM
risk and also appear to decrease the risk for PTB via the reduction of vaginal infections such as BV.

Preeclampsia
The relationships between the microbiome, prebiotic, probiotic, or synbiotic use and the risk for PEC are not
fully understood. However, the findings of this review suggest that more research is justified, given the findings
that (a) placental tissues of women with PEC were found to harbor pathogenic microbes along with signs of
placental inflammation and (b) probiotic use is associated with a reduction in PEC risk. Although there were a
limited number of studies identified, the findings suggest that more research is needed to explore these

biological mechanisms as viable pathways in the complex pathophysiologic pathway underpinning PEC. Future
well-controlled RCTs to explore causal relationships between probiotic use and PEC risk are needed.
It may be beneficial to explore the relationships between the microbiome, microbial interventions, and PEC
incidence in high-risk groups. Considering the inflammatory state of obesity and the increased risk of
hypertensive disorders of pregnancy among obese pregnant women, a recent study associated with an RCT
(study of probiotics in GDM) explored whether select gut microbes and metabolites among obese pregnant
women influenced gestational blood pressure. Overweight and obese pregnant women were found to have gutassociated metabolites (odoribacter and butyrate) that inversely correlated with systolic blood pressure
endothelial markers (plasminogen activator inhibitor 1), suggesting that the microbiome may influence blood
pressure regulation in pregnancy.93 Future microbiome-related studies among obese pregnant women may
prove beneficial in understanding the pathology of PEC and GDM, given the increased prevalence of obesity.

Preterm birth
The volume of microbiome studies seeking to identify bacterial communities associated with PTB is extensive.
Researchers, utilizing descriptive and correlational studies, attempted to find microbial predictors of premature
labor. While all the RCTs sought to reduce PTB risk,39,48,50 prevention and treatment of infections using probiotic
interventions, particularly for BV, were important aims.36,49 Probiotics have been shown to be an effective
independent or adjunctive therapy for BV.94
Disparities in perinatal outcomes disproportionately impact African American women and their families. The
findings of this scoping review suggest that the vaginal flora of African American women may predispose them
to PTB risk. Customized nutritional interventions with prebiotics, probiotics, or synbiotics95 may offer low-risk
strategies for primary prevention.
Premature labor and birth are often the result of polymicrobial infection96 with organisms of vaginal origin.35
Vaginal dysbiosis increases the risk of preterm premature rupture of the membranes and neonatal sepsis.61
Based on the studies reviewed, these findings provide opportunities for effective prevention and/or intervention
at the microbial level. Studies on microbial aspects of PTB prevention require adequate statistical power to
demonstrate efficacy of interventions.

Gestational diabetes
Since GDM is nonacute and diagnosed at predictable intervals during pregnancy, it is compatible with
prospective study. Thus, GDM has received considerable attention in RCTs of probiotic interventions. Healthy
women were enrolled in 2 studies.46,47 Findings from both studies demonstrated that probiotic interventions
reduced the incidence of GDM.46,47 The remaining RCTs used samples of women with GDM and focused on
interventions with probiotics to improve metabolic outcomes. In contrast, there is a dearth of research on the
microbiome associated with GDM. Since inflammation is associated with GDM, more research in this area is
warranted.
Although not detailed in this review, Bifidobacterium and Lactobacillus were the most studied species of
probiotics in GDM RCTs. Probiotic strains and dosages varied greatly between studies. For example, 1 study used
only 1 million colony-forming units of a single probiotic strain,44 while another used a multispecies probiotic with
1 trillion colony-forming units.42 In their meta-analysis of probiotics and GDM, Zheng et al33 suggested that a
probiotic dose of greater than 107 colony-forming units may lead to the most benefit. The authors concluded
that antenatal probiotic interventions had a favorable effect on glucose metabolism.33 More well-controlled
trials of the efficacy of various well-characterized probiotic strains and dosages on GDM diagnosis and metabolic
outcomes are needed.

Conclusions
The role of the microbiome in PEC, PTB, and GDM is not fully elucidated, although findings from this review
suggest that pathogenic microbes in a variety of habitats including the placenta, oral cavity, vagina, and gut may
influence the risk for adverse pregnancy outcomes. Although distinct microbial profiles were not identified in
select outcomes, probiotics appear to be effective in reducing the risk for PEC, PTB, and GDM in some cases.
Probiotic interventions were not associated with adverse events and were well tolerated by the participants. In
studies, all 3 entities covered in this review, PEC, GDM, and PTB, were associated with an increase in markers of
systemic inflammation.4,54 Future studies investigating the role of the microbiome on a variety of inflammatory
pathways may help elucidate biological pathways underpinning microbial dysbiosis. In addition, laboratory
technologies used to study the metagenomics are complex and continually evolving.64 For example, the analyses
can be expensive, time-consuming, and dependent on databases that are imperfect. Newer next-generation
sequencing will likely improve accuracy.64 More research in this area in conjunction with advanced molecular
sequencing technologies could significantly impact perinatal outcomes for women who experience any of these
high-risk complications.
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